A clutch of deals including a $1 billion offering of shares and pre-funded warrants kicked off what could be a busy fall for share sales of already-public companies on US exchanges.
Vaxcyte Inc., a clinical stage vaccine company, led the charge with its $1 billion deal, just hours after reporting data from a recent study that sent its stock surging 36% Tuesday to a record close of $110.15.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.